The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M01 | Antiinflammatory and antirheumatic products | |
| 3 | M01C | Specific antirheumatic agents | |
| 4 | M01CB | Gold preparations |
| Code | Title | |
|---|---|---|
| M01CB01 | Sodium aurothiomalate | |
| M01CB02 | Sodium aurotiosulfate | |
| M01CB03 | Auranofin | |
| M01CB04 | Aurothioglucose | |
| M01CB05 | Aurotioprol |
| Active Ingredient | Description | |
|---|---|---|
| Auranofin |
Auranofin is an orally available compound, used to treat rheumatoid arthritis, with anti-inflammatory activities. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes such as thioredoxin reductase (TrxR). The thiol ligand contained in auranofin has a high affinity for thiol and selenol groups, to which it forms stable, and irreversible, adducts. Redox enzymes such as TrxR are essential to many cellular processes, particularly in maintaining the intracellular levels of reactive oxygen species (ROS). |
|
| Sodium aurothiomalate |
|
